PDCD1 and glioblastoma: Our results suggested that targeting ALKBH5 improved the tumor immune microenvironment and enhanced the efficacy of anti-PD-1 therapy through the acceleration of PD-L1 degradation, which provides a promising combination therapeutic strategy for GBM.